By Sabela Ojea
Incyte and Syndax Pharmaceutical said the Food and Drug Administration approved their graft disease treatment Niktimvo antibody in nine milligram and 22 milligram vial sizes.
The biopharmaceutical companies on Wednesday said that they expect the product to be available for order in the U.S. early in February. Incyte has exclusive commercialization rights for Niktimvo outside the U.S.
Niktimvo was approved by the FDA on Aug. 14 for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kilograms. Graft-versus-host disease is a severe complication that can occur following hematopoietic stem cell transplantation.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
January 15, 2025 18:12 ET (23:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。